

FY2024 Second Quarter

(Ended February 28, 2025)

Financial Briefing



Oct 15, 2024
RORZE CORPORATION
(Code : 6323)
<https://www.rorze.com/ir>

Disclaimer

◆ Regarding forward-looking statements

The business forecasts and other forward-looking statements contained in this document are based on judgments made in accordance with information currently available for our company and do not constitute a guarantee or promise of the accuracy or completeness of such information. The forecast is also subject to change without notice due to changes in economic conditions, industry competition, markets and other systems.

◆ Data included in this document are stated as follows


- JPY values : Rounded down to the nearest unit
- Percentages : Rounded to the nearest unit after calculated in units of 1 JPY
- Fiscal year : Refer to the "fiscal year ended February 28, 2025" as "FY2024" or "FY'24,"
- Accounting period : The accounting periods of the consolidated, head office, and domestic and overseas subsidiaries are as follows:

	Q1 (1st Quarter)	Q2 (2nd Quarter)	Q3 (3rd Quarter)	Q4 (4th Quarter)	Full-year
Consolidated ・ RORZE ・ Domestic subsidiaries	Mar.～May.	Jun.～Aug.	Sep.～Nov.	Dec.～ The following Feb.	Mar.～ The following Feb.
Overseas subsidiaries	Jan.～Mar.	Apr.～Jun.	Jul.～Sep.	Oct.～Dec.	Jan.～Dec.


Company Profile


Name	RORZE CORPORATION
Listed Market	Tokyo Stock Exchange Prime Market (Securities code : 6323)
Head Office	1588-2 Michinoue Kannabe-cho, Fukuyama-shi, Hiroshima
Establishment	March 30, 1985
Capital	982 million JPY
Business	Development, design, manufacturing, and sales of automation system for semiconductor/FPD production and life science automation products
Employees	Consolidated : 4,121 Non-consolidated : 242 (As of August 31, 2024)
Locations	Japan : Fukuyama · Yokohama · Kumamoto · Tsukuba · Hino Overseas : USA / Vietnam / Taiwan / Korea / Singapore/ China / Germany

Number of employees (consolidated)



Global Network





FY2024
Second Quarter
(March 1, 2024~August 31, 2024)
Consolidated Business Results

Summary of Q2 FY2024

- Sales of Semi and FPD increased, and achieved profit increase with foreign exchange gains under weaker JPY

		YOY
■ Net sales	60,229 million JPY	+46.9%
■ Operating profit	17,146 million JPY	+72.3%
■ Ordinary profit	20,574 million JPY	+48.3%
■ Profit attributable to owners of parent	15,850 million JPY	+61.2%


Exchange rate

(Yen/USD)

FY'24 Initial Forecast	FY'24 H1	FY'24 H2 Forecast
144	152	144

※ Starting from this fiscal year, performance forecasts and actual results are based on the average rate for the period.


Sale composition ratio



Quarterly Sales

(Million JPY)	Q2 FY'23	Q3	Q4	Q1 FY'24	Q2
■ Service/Parts※	1,582	1,490	1,638	1,705	2,122
■ Life science	52	148	919	152	181
■ FPD	1,368	846	1,152	262	3,130
■ Analysis device	805	849	742	331	1,030
■ Semi	20,489	20,836	23,632	26,836	24,475

※ From the current fiscal year, "motor control equipment" is included in "Service/Parts etc.".



FY2024 Q2 business result

- Sales of Semi and FPD Sales steadily increased , and with foreign exchange gains ensured a profit


(Million JPY)

	FY'24 Q2 Achievements	FY'23 Q2 (Previous year)	YoY (%)	FY'24 Q2 Forecast	FY'24 Q2 Progress rate(%)
Net Sales	60,229	40,992	146.9	61,474	98.0
Semi	51,311	34,477	148.8	52,099	98.5
Analysis device	1,362	1,521	89.6	2,373	57.4
FPD	3,392	1,715	197.8	3,348	101.3
Life science	334	152	218.7	311	107.4
※Service/Parts etc.	3,828	3,126	122.4	3,342	114.5
Operating Profit	17,146	9,952	172.3	17,298	99.1
Ordinary Profit	20,574	13,878	148.3	17,300	118.9
Attributable to parent company shareholders Quarterly (current) Net Profit	15,850	9,835	161.2	12,604	125.8







※ From the current fiscal year, "motor control equipment" is included in "Service/Parts etc."

Net sales by regions

- Semi sales to China temporarily decreased but kept upward trend, and FPD sales to Korea increased




※ "Net sales by region" is calculated based on the head quarter of each customer locates



Operating profit drivers (Cumulative period)

- Higher Semi sales led the higher profit


(Million JPY)



Trends in orders, sales, and backlog

Semiconductor
related equipment

- Sales amount decreased, mainly in China, QoQ by 2.3 billion JPY
- Order amount increased, mainly from the key customers in China and Taiwan, QoQ by 3.1 billion JPY




Trends in orders, sales, and backlog

Analysis equipment

- Orders and equipment deliveries proceed smoothly, while pending acceptance at customer sites remained at the high level

(Million JPY)




Trends in orders, sales, and backlog

FPD



- Sales amount increased through the shipment of the large substrate transfer system booked in Q2 FY'23
- Order amount will include approx. 3.6 billion JPY in Q3 from a major customer in Korea

(Million JPY)




Consolidated balance sheet


- Cash and deposits increased through higher accounts receivable collection
- Consolidation of Nanoverse Technologies, Ltd. as a subsidiary;
(Total asset 10.7 billion JPY、 Goodwill 9.1 billion JPY、 Loans 3.5 billion JPY)



FY2024 Second Quarter Cash Flow

(Million JPY)





FY2024 Second Quarter Business Forecast

Impact of Typhoon No. 11 on Vietnam manufacturing subsidiary

Disaster Date	Saturday, September 7 th , 2024
Human Casualties	No harm to employees
Damage to buildings, production facilities, etc.	<ul style="list-style-type: none">• Estimated Amount of Damage : 443 million JPY (factory building, equipment, inventories, etc.) Most of the estimated damage will be covered by insurance• In response to partial roof and wall peeling from strong winds and product damage from rainwater intrusion, production resumed by relocating equipment from the damaged building. Production capacity has recovered in line with the recovery plan.• Production delays are approximately 2 weeks as of early October and will be resolved by the end of November

Consolidation of Nanoverse Technologies, Ltd. as a subsidiary

Company name (Location)	Nanoverse Technologies, Ltd. (Oregon, USA)	
Business Contents	Development, manufacture and sales of semiconductor manufacturing equipment (laser scribes and metrology equipment)	
Main reasons for consolidation of subsidiary	By effectively utilizing the Nanoverse's laser, optics and software technologies with the management resources such as RORZE's core technologies, service network and production capabilities, the two companies will realize further growth in the semiconductor equipment business	
Date of acquisition of shares	June 26, 2024	Acquisition of shares through a third-party allotment
Percentage of voting rights acquired	33.0%	Acquisition of shares in exchange for cash
Acquisition cost	70 million USD (cash)	approximately 11 billion JPY equivalent by 158 JPY/USD
Amount of goodwill accrued	9,112 million JPY (provisional)	Generated from excess profitability expected through future business development
Depreciation method and depreciation period	Undecided at this time (currently under discussion)	
Interim Consolidated Settlement	As of August 31, 2024, only the balance sheet is consolidated, not included in the income statement	
Expected impact on consolidated earnings forecasts	<p>Expected impact on operating profit in the second half: approximately 3.5 billion JPY (Maximum of each; amortization of goodwill: approximately 1.5 billion JPY, SG&A expenses: approximately 2.0 billion JPY) ※Nanoverse's current performance forecast for the next fiscal year and beyond is as follows: Fiscal Year Ending February 2026: final Loss of approximately 8 billion JPY – Expected impact of R&D ahead Fiscal Year Ending February 2027: approximately 1.2 billion JPY in profitability - Expected to generate sales from shipment of developed equipment</p>	


FY2024 Progress against business forecasts

- Mainstay Semi sales are to stay strong in H2 driven by sales to China, the U.S. and Taiwan.
- Exchange rate, weaker JPY than initial forecast in H1, is expected to stay in line with initial forecast(144 JPY/USD)
- Considering core business performance, exchange rates, and investee conditions, the full-year consolidated earnings forecast remains unchanged.

(Million JPY)

	FY'24 Q2 Achievements	FY'24 Full-year forecast	Full-year forecast Progress rate(%)
Net Sales	60,229	120,784	49.9
Semi	51,311	102,399	50.1
Analysis device	1,362	3,841	35.5
FPD	3,392	6,511	52.1
Life Science	334	1,300	25.7
※ Service/Parts etc.	3,828	6,732	56.9
Operating Profit	17,146	31,617	54.2
Ordinary Profit	20,574	31,518	65.3
Attributable to parent company shareholders Quarterly (current) Net Profit	15,850	22,916	69.2

※ From the current fiscal year, "motor control equipment" is included in "Service/Parts etc."




Topics

Construction of a new plant at a subsidiary in Vietnam

- Respond to growing demand and innovation in Semi industry to strengthen competitiveness and achieve sustainable growth.
 - Doubling production capacity
 - Rising the production capacity of existing products to meet future demand
 - Establishment of a mass production system for newly developed products
 - Automate production lines and improve production efficiency
 - Expansion of R&D Design Capabilities

Location	Hai Phong City, Vietnam Japan Hai Phong Industrial Park (in the current factory and the same industrial park)
Investment Details	Land, buildings, production equipment etc.
Land area	Approx. 238,300 m ²
Total floor area of the plant	Approx. 180,000 m ²
Planned Implementation Period	Mid-2025~2032 ※Phased implementation is planned Phase 1 construction is expected to begin in the spring of 2026 and to be completed in the spring of 2027 After that, it will be implemented sequentially in consideration of market trends.
Total Investment	Approx. 330 million USD


RORZE Lifesciences' Acquisition of Genostaff



Location	Yayoi, Bunkyo-ku, Tokyo
Business Description	Contract research of histological staining and gene function analysis, and related products sales
Establishment	February 2002
Capital	42 million JPY
Sales	238 million JPY (FY2024/3 rd term results)
Employees	12

<https://genostaff.com>

< Tissue staining* >



< Device >




Automatic Paraffin Embedding Machine
(Manufactured by RORZE Life Sciences)

Synergies in the drug discovery support business

- Establish a highly reliable testing outsourcing system using Company RORZE Life Science's facilities
- New fields of molecular pathology and engineering automation

* Accurate tissue staining is one of the deciding factors to visualizing results like determining paper acceptance.



References

RORZE

Unit



Atmospheric
Robot



Aligner



Load Port

System



EFEM



Vacuum Platform

System



Wafer Sorter



N2 Purge Wafer Stocker

Equipment
manufacturers(SPE)

Process equipment
Inspection equipment


End -user

Device manufacturers
Wafer manufacturers

Advanced packaging line

Advanced packaging

Method for connecting chiplet to achieve higher device density and functionality expansion with a smaller footprint



Advanced packaging line



PLP EFEM



Tape Frame Sorter



Analysis device




Semiconductor industry
SPEs
End-user
Device manufacturers
Wafer manufacturers

Other industry
Research institution
Environmental measuring
Instrument manufacturer
Chemical manufacturer etc.


FPD

RORZE


RORZE SYSTEMS
(Subsidiary in Korea)



INDEX extra-large substrate transfer system




In-line returnable transfer system



Laser cutting equipment



Front-end :
FPD manufacturers
Glass for FPD
manufacturers



Display module equipment



Cell type extra-large packing equipment



Back-end :
FPD manufacturers

Life science



Incubator
SCALE48



CO₂ Incubator with medium exchange
function & cell imaging function
CellKeeper® II 48Plus



Automatic medium
exchange system
CellFarm(L)-360™



Scheduling software
Green Button Go™ ※
(※Product of Biosero)



Mobile robot

Drug discovery,
Regenerative
medicine
(universities,
pharmaceutical
companies)

Thank you

